A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP Study
Principal Investigator
Ann Klopp, MD
Status
Terminated
Date Opened To Accrual
November 28 2012
Date Closed to Accrual
August 27 2015
Date of Study Termination
May 20 2022
Disease Site
Gynecologic [GY]
Other
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if IMRT reduces acute gastrointestinal toxicity in the 5th week (after 23-25 fractions) of pelvic radiation as measured with EPIC.
Patient Population
Pathologically proven diagnosis of endometrial and cervical cancer who require post-operative radiation or chemoradiation; Zubrod performance status of 0–2.
Target Accrual
281
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.